Repligen | RGEN - Debt



Repligen reported $533.72M in Debt for its fiscal quarter ending in June of 2025.


Debt Change Date
Agilent USD 3.41B 86M Jul/2025
Align Technology USD 118.54M 118.54M Mar/2025
Bio Techne USD 346M 16M Jun/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Bristol-Myers Squibb USD 50.93B 1.22B Jun/2025
Bruker USD 2.44B 321.5M Jun/2025
Charles River Laboratories USD 2.79B 275.28M Jun/2025
Danaher USD 17.36B 878M Jun/2025
Dentsply International USD 2.49B 159M Jun/2025
Exact Sciences USD 2.32B 16.28M Jun/2025
General Electric Aerospace USD 18.89B 684M Jun/2025
Henry Schein USD 3.36B 467M Jun/2025
Illumina USD 2.6B 608M Jun/2025
IQVIA Holdings USD 15.49B 1.16B Jun/2025
Mettler Toledo International USD 2.18B 109.83M Jun/2025
Myriad Genetics USD 59.3M 19.7M Mar/2025
Pfizer USD 60.93B 1.18B Jun/2025
Repligen USD 533.72M 149.97M Jun/2025
Revvity USD 3.17B 17.91M Mar/2025
Standard Biotools USD 28.62M 28.32M Jun/2025
Thermo Fisher Scientific USD 34.19B 2.91B Mar/2025
Waters USD 1.54B 81.64M Jun/2025
West Pharmaceutical Services USD 202.6M 0 Jun/2025